Answer:
As sickle cell disease is caused by a genetic mutation, it is a perfect candidate for CRISPR-mediated gene therapy. Treating sickle cell anemia with CRISPR involves an ex vivo procedure known as gene-edited cell therapy, where hematopoietic stem cells are extracted from the patient, corrected, and then replaced.
Explanation:
